Is headache on liraglutide dose-dependent or dose-rate dependent?

The particulars: headache · liraglutide.

I want to know whether this is a real physical effect or an artefact of how it is measured.

What prompted the question is an inconsistency between two sources I otherwise trust.

Is the standard explanation correct, and if so, what is the evidence for it?

The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Specifically, liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

The top of the schedule is not the target. The working dose is.

It helps to be literal here: this is the single most consequential controllable variable in the whole experience, and people routinely rush it.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Stepping back is a normal adjustment, not a failure.

More usefully, the initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.

Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

Hold rather than escalate while symptoms are active. Always.

The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Slower costs time and nothing else. The ceiling is the same.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.

Four half-lives between steps, minimum. Work it out for your agent.

edited 8 Mar 2026 by Dr_Hanne_Solberg — clarified the distinction between purity and content